Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
Obstetrics & Gynecology Science
;
: 285-289, 2019.
Artigo
em Inglês
| WPRIM
| ID: wpr-760645
ABSTRACT
The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Ovarianas
/
Cavidade Peritoneal
/
Neoplasias Peritoneais
/
Recidiva
/
Carboplatina
/
Cisplatino
/
Paclitaxel
/
Topotecan
/
Tratamento Farmacológico
/
Infusões Parenterais
Limite:
Humanos
Idioma:
Inglês
Revista:
Obstetrics & Gynecology Science
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS